Research

LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly

    • 1Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, United Kingdom;
    • 2Retrovirus-Host Interactions, The Francis Crick Institute, London NW1 1AT, United Kingdom;
    • 3Mass Spectrometry Proteomics, The Francis Crick Institute, London NW1 1AT, United Kingdom;
    • 4Department of Medicine, Faculty of Medicine, Imperial College, London W2 1PG, United Kingdom;
    • 5The Jenner Institute, University of Oxford, Oxford OX3 7DQ, United Kingdom
    • 6 These authors contributed equally to this work.
Published September 19, 2019. https://doi.org/10.1101/gr.248922.119
Download PDF Cite Article Permissions Share
cover of Genome Research Vol 36 Issue 6
Current Issue:

Abstract

Dysregulated endogenous retroelements (EREs) are increasingly implicated in the initiation, progression, and immune surveillance of human cancer. However, incomplete knowledge of ERE activity limits mechanistic studies. By using pan-cancer de novo transcript assembly, we uncover the extent and complexity of ERE transcription. The current assembly doubled the number of previously annotated transcripts overlapping with long-terminal repeat (LTR) elements, several thousand of which were expressed specifically in one or a few related cancer types. Exemplified in melanoma, LTR-overlapping transcripts were highly predictable, disease prognostic, and closely linked with molecularly defined subtypes. They further showed the potential to affect disease-relevant genes, as well as produce novel cancer-specific antigenic peptides. This extended view of LTR elements provides the framework for functional validation of affected genes and targets for cancer immunotherapy.

Loading
Loading
Loading
Back to top